Findings from the HELEN-006 trial suggest a potential shift in neoadjuvant treatment practices for patients with HER2-positive early breast cancer, specifically using nab-paclitaxel to reduce ...
The new drug, Jazz Pharmaceuticals’ zanidatamab, has won an FDA accelerated approval for adults with previously treated ...
Sarah Sammons, MD, discusses some of the challenges seen with different regimens for HER2-positive metastatic breast cancer ...
Real-world outcomes for HER2-positive NSCLC differ from clinical trials due to diverse patient populations and treatment ...
A review of recent clinical trial results for emerging HER2-directed therapies, including SOHO-01, inetetamab/pyrotinib, and ...
One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...
新研究表明在HER2阳性乳腺癌患者中，胚系BRCA1/2突变的发生率为6.6%，且不影响生存结果。乳腺癌是女性最常见的恶性肿瘤，遗传易感性作为其主要风险因素，在全部乳腺癌病例中占比达5%-10%。其中，约50%的病例与乳腺癌相关基因BRCA1和BRC ...
*仅供医学专业人士阅读参考不同ER和PR表达模式的HER2阳性早期乳腺癌患者的临床病理学特征和预后存在差异，其对个体化治疗策略的影响值得关注。乳腺癌是一种异质性疾病，具有多种分子亚型和基因型特征[1]。HER2阳性乳腺癌约占总体乳腺癌的15%–20% ...
Jazz Pharmaceuticals has claimed FDA approval for its HER2-directed bispecific antibody Ziihera as a treatment for biliary ...
This infographic, the first in a three-part series, explores the development of resistance to endocrine therapy in ...
News Medical on MSN11d
New CAR T-cell therapy shows promise against aggressive HER2+ breast cancerOne-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...
An expert discusses the next steps for patients with metastatic breast cancer after their disease no longer responds to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback